A retrospective study of the efficacy and safety of levofloxacin in children with severe infection.

PICU children infection levofloxacin quinolone

Journal

Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492

Informations de publication

Date de publication:
2024
Historique:
received: 04 02 2024
accepted: 18 03 2024
medline: 22 4 2024
pubmed: 22 4 2024
entrez: 22 4 2024
Statut: epublish

Résumé

Levofloxacin is widely used because of its broad-spectrum antimicrobial activity and convenient dosing schedule. However, the relevance of its use in children remains to be investigated. The purpose of this study is to investigate the efficacy and safety of levofloxacin use in children with severe infections. We conducted a retrospective observational study of patients <18 years of age who received levofloxacin intravenously in the Pediatric Intensive Care Unit (PICU) of our hospital during the period between 2021 and 2022. Patient demographics, course characteristics, clinical effectiveness, and adverse event correlations were extracted through a retrospective tabular review. We included 25 patients treated with 28 courses of levofloxacin. The mean age of these children treated with levofloxacin was 4.41 years. Conversion of pathogenic microbiological test results to negative after levofloxacin treatment was detected in 11 courses (39.29%). A decrease in inflammatory markers, white blood cell or C-reactive protein counts, was detected in 18 courses (64.29%). A total of 57 adverse events occurred during the treatment period, of which 21 were possibly related to levofloxacin and no adverse events were probably related to levofloxacin. The effectiveness of levofloxacin use in children with serious infections is promising, especially for the treatment of multidrug-resistant bacteria. Adverse events occurring during the initiation of levofloxacin therapy in children are reported to be relatively common, but in this study, only a small percentage of them were possibly related to levofloxacin, and none of them were highly possibly related to levofloxacin.

Identifiants

pubmed: 38646513
doi: 10.3389/fped.2024.1381742
pmc: PMC11026612
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1381742

Informations de copyright

© 2024 Junqi, Jie, Jinglin, Jinmiao, Guoping, Yi and Zhiping.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Zhang Junqi (Z)

Department of Clinical Pharmacy, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.

Cai Jie (C)

Department of Clinical Pharmacy, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.

Wang Jinglin (W)

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Lu Jinmiao (L)

Department of Clinical Pharmacy, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.

Lu Guoping (L)

Pediatric Intensive Care Unit, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.

Wang Yi (W)

Department of Neurology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.

Li Zhiping (L)

Department of Clinical Pharmacy, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.

Classifications MeSH